Katie Snoke
Adult Health · Casselberry, FLNPI 1508377433
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 9.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,012 and has fallen 66.6% since, to $672 in 2025. Among adult health clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$505
- Actelion Pharmaceuticals US, Inc.$444
- Pfizer$417
- Johnson & Johnson$412
- United Therapeutics Corporation$398
- Merck$303
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,635100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 22 | $505 |
| Actelion Pharmaceuticals US, Inc. | 10 | $444 |
| Pfizer | 24 | $417 |
| Johnson & Johnson | 31 | $412 |
| United Therapeutics Corporation | 9 | $398 |
| Merck | 19 | $303 |
| Kestra Medical Technology Services, Inc. | 4 | $299 |
| Bayer | 14 | $280 |
| Amgen | 8 | $243 |
| Amarin Pharma, Inc. | 12 | $240 |
| Alnylam Pharmaceuticals Inc. | 9 | $228 |
| Novartis | 12 | $226 |
| Atricure, Inc. | 4 | $184 |
| E.r. Squibb & Sons, L.L.C. | 10 | $166 |
| Novo Nordisk | 12 | $157 |
| Cvrx, Inc. | 6 | $141 |
| Esperion Therapeutics, Inc. | 6 | $124 |
| Impulse Dynamics (USA) Inc. | 6 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $80 |
| Regeneron Healthcare Solutions, Inc. | 2 | $78 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $75 |
| Arbor Pharmaceuticals, Inc. | 5 | $62 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Abbott | 3 | $55 |
| Tactile Systems Technology Inc | 4 | $55 |
| AstraZeneca | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 1 | $34 |
| Vifor Pharma, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Bard Peripheral Vascular, Inc. | 1 | $21 |
| Davol Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $20 |
| 3b Medical, Inc. | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$268
- OPSUMIT$268
- Assure WCD$137
- Repatha$122
- XARELTO$114
- SYNERGY ABLATION SYSTEM$113
- JARDIANCE$107
How this compares
$5,635 in reported general payments places this provider in the 90th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 18 | $571,120 |
| Orenitram ErTreprostinil Diolamine | 22 | $418,244 |
| EliquisApixaban | 252 | $318,750 |
| JardianceEmpagliflozin | 108 | $120,763 |
| XareltoRivaroxaban | 101 | $97,468 |
| EntrestoSacubitril/Valsartan | 63 | $78,765 |
| Repatha SureclickEvolocumab | 50 | $43,324 |
| FarxigaDapagliflozin Propanediol | 34 | $34,080 |
| VascepaIcosapent Ethyl | 38 | $32,858 |
| BrilintaTicagrelor | 28 | $25,692 |
| Praluent PenAlirocumab | 32 | $18,905 |
| MounjaroTirzepatide | 15 | $18,851 |
| JanuviaSitagliptin Phosphate | 14 | $14,694 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 16 | $8,690 |
| EdarbiAzilsartan Medoxomil | 11 | $3,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $417 | $889,869270 claims |
| Boehringer IngelheimJardiance | $505 | $120,763108 claims |
| Johnson & JohnsonXarelto | $412 | $97,468101 claims |
| NovartisEntresto | $226 | $78,76563 claims |
| AstraZenecaFarxiga, Brilinta | $45 | $59,77362 claims |
| MerckJanuvia | $303 | $14,69414 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $62 | $12,34427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,237 adult health providers in Florida.
Other adult health in Casselberry
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Cynthia OteroMaitland$31K
- Jennifer GodshallTampa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.